ELI LILLY & Co. - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Eli Lilly and Company operates as a single segment engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products globally. The company reported a significant increase in revenue driven by high demand for its cardiometabolic portfolio, specifically Mounjaro and Zepbound.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $12,728.5 million | $8,768.0 million |
| Net Income | $2,759.3 million | $2,242.9 million |
| Diluted EPS | $3.06 | $2.48 |
| Gross Margin | 82.5% | 80.9% |
| Operating Cash Flow | $1,665.6 million | $1,166.0 million |
| Total Debt | $38.52 billion | $33.64 billion (Dec 2024) |
| Cash & Equivalents | $3.09 billion | $3.27 billion (Dec 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 45% year-over-year, driven by a 53% volume increase. U.S. revenue grew 49% and non-U.S. revenue grew 38%. Growth was primarily fueled by Mounjaro (up 113% total) and Zepbound (up significantly from $517.4M to $2.31B).
- Acquired IPR&D: A significant one-time charge of $1.57 billion was recorded for acquired in-process research and development, primarily related to the acquisition of Scorpion Therapeutics' PI3Kα inhibitor program. This compares to $110.5 million in Q1 2024.
- Expenses: Marketing, selling, and administrative expenses rose 26% to $2.47 billion due to promotional efforts. R&D expenses increased 8% to $2.73 billion.
- Tax Rate: The effective tax rate increased to 20.2% from 11.6%, largely due to the non-deductible nature of the acquired IPR&D charge.
- Debt Issuance: In February 2025, the company issued $6.50 billion in fixed-rate notes to fund the Scorpion acquisition and repay commercial paper.
Outlook, Risks, and Management Commentary
- Supply Chain: Tirzepatide supply currently exceeds demand in the U.S., though the company notes that complex supply chains may still cause periodic unavailability of specific doses. The company is actively addressing counterfeit and compounded incretin products.
- Regulatory & Pricing: The Inflation Reduction Act (IRA) continues to impact strategy, with Jardiance selected for government-set pricing starting in 2026. The company faces ongoing litigation regarding insulin pricing and the 340B program.
- Clinical Updates: Positive Phase 3 results were announced for orforglipron (oral GLP-1). However, the EMA issued a negative opinion for donanemab for Alzheimer's disease, though the company is seeking re-examination.
- Capital Allocation: The company repurchased $1.20 billion of shares in Q1 2025, leaving $13.80 billion remaining under its $15.00 billion program. Dividends paid were $1.35 billion ($1.50 per share).
Investor Verification Checklist
- Acquisition Impact: Verify the long-term commercial viability and regulatory timeline for the Scorpion Therapeutics PI3Kα inhibitor program given the $1.57 billion immediate expense.
- Supply Constraints: Monitor updates on tirzepatide manufacturing capacity and the resolution of counterfeit product issues in the market.
- Regulatory Risks: Track the status of the EMA re-examination for donanemab and the outcome of ongoing insulin pricing litigation and 340B program challenges.
- Debt Servicing: Assess the impact of the increased debt load ($38.52 billion) on future interest expenses and liquidity, particularly given the new fixed-rate notes issued in early 2025.
- Product Mix: Evaluate the sustainability of revenue growth from Mounjaro and Zepbound as the company faces potential pricing pressures from the IRA and increased competition.